

Molecular composition and heterogeneity of the LRRC8-containing swelling-activated osmolyte channels in primary rat astrocytes

Alexandra L. Schober, Corinne S. Wilson and Alexander A. Mongin 

Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, NY 12208, USA

Key points

- The volume-regulated anion channel (VRAC) is a swelling-activated chloride channel that is permeable to inorganic anions and a variety of small organic molecules.
- VRAC is formed via heteromerization of LRRC8 proteins, among which LRRC8A is essential, while LRRC8B/C/D/E serve as exchangeable complementary partners.
- We used an RNAi approach and radiotracer assays to explore which LRRC8 isoforms contribute to swelling-activated release of diverse organic osmolytes in rat astrocytes.
- Efflux of uncharged osmolytes (*myo*-inositol and taurine) was suppressed by deletion of LRRC8A or LRRC8D, but not by deletion of LRRC8C+LRRC8E.
- Conversely, release of charged osmolytes (D-aspartate) was strongly reduced by deletion of LRRC8A or LRRC8C+LRRC8E, but largely unaffected by downregulation of LRRC8D.
- Our findings point to the existence of multiple heteromeric VRACs in the same cell type: LRRC8A/D-containing heteromers appear to dominate release of uncharged osmolytes, while LRRC8A/C/E, with the additional contribution of LRRC8D, creates a conduit for movement of charged molecules.

Abstract The volume-regulated anion channel (VRAC) is the ubiquitously expressed vertebrate Cl⁻/anion channel that is composed of proteins belonging to the LRRC8 family and activated by cell swelling. In the brain, VRAC contributes to physiological and pathological release of a variety of small organic molecules, including the amino acid neurotransmitters glutamate, aspartate and taurine. In the present work, we explored the role of all five LRRC8 family members in the release of organic osmolytes from primary rat astrocytes. Expression of LRRC8 proteins was modified using an RNAi approach, and amino acid fluxes via VRAC were quantified by radiotracer assays in cells challenged with hypoosmotic medium (30% reduction in osmolarity). Consistent with our prior work, knockdown of LRRC8A potently and equally suppressed the release of radiolabelled D-[¹⁴C]aspartate and [³H]taurine. Among other LRRC8 subunits, downregulation of LRRC8D strongly inhibited release of the uncharged osmolytes [³H]taurine and *myo*-[³H]inositol, without major impact on the simultaneously measured efflux of the charged D-[¹⁴C]aspartate. In contrast, the release of D-[¹⁴C]aspartate was preferentially sensitive to deletion of LRRC8C+LRRC8E, but unaffected by downregulation of LRRC8D. Finally, siRNA knockdown of LRRC8C+LRRC8D strongly inhibited the release of all osmolytes. Overall, our findings suggest the existence of at least two distinct heteromeric VRACs in astroglial cells. The LRRC8A/D-containing permeability

A. L. Schober and C. S. Wilson contributed equally to this work and therefore should be considered co-first authors.

The results of this study were reported in a preliminary form at the 11th International Congress on Cell Volume Regulation and Fluid Homeostasis. Schober AL & Mongin AA (2016). Evidence for multiple LRRC8-containing organic osmolyte release pathways in glial cells of the brain. Abstract Book. p. 71. DePaul University, Chicago, IL, August 15–18, 2016.

pathway appears to dominate the release of uncharged osmolytes, while an alternative channel (or channels) is composed of LRRC8A/C/D/E and responsible for the loss of charged molecules.

(Resubmitted 2 August 2017; accepted after revision 14 August 2017; first published online 22 August 2017)

Corresponding author: A. A. Mongin: Albany Medical College, 47 New Scotland Ave. (MC-136), Albany, NY 12208, USA. Email: mongina@mail.amc.edu

Abbreviations GABA, γ -aminobutyric acid; LRRC8, leucine-rich repeat containing 8; RVD, regulatory volume decrease; VRAC, volume-regulated anion channel.

Introduction

The volume-regulated anion channel (VRAC) is the physiologically essential anion/osmolyte release pathway that allows animal cells to regulate their volume when they encounter osmotic swelling. The principal role of VRAC is an 'emergency' release of Cl^- and other inorganic anions, such as HCO_3^- , which accompanies and facilitates the loss of intracellular K^+ and osmotically obligated water (Nilius *et al.* 1997; Okada, 1997; Lang *et al.* 1998; Mongin & Orlov, 2001; Hoffmann *et al.* 2009). Since their initial discovery in lymphocytes and epithelial cells, swelling-activated Cl^- currents have been identified in nearly every vertebrate cell type studied, but their molecular identity remained unknown (Cahalan & Lewis, 1988; Hazama & Okada, 1988; Strange *et al.* 1996; Nilius *et al.* 1997; Okada, 1997; Pedersen *et al.* 2016). Two recent seminal studies independently discovered that VRAC is formed by proteins belonging to the family of leucine-rich repeat containing 8 (LRRC8) (Qiu *et al.* 2014; Voss *et al.* 2014). Among the five homologous LRRC8 proteins, LRRC8A (or SWELL1) appears to be essential for channel function but must heteromerize with at least one additional isoform, LRRC8B–E (Qiu *et al.* 2014; Voss *et al.* 2014; Stauber, 2015; Jentsch, 2016). Based on the pannexin homology, it has been predicted that VRAC is a hexameric channel with one central pore; however, octameric assembly is also possible based on the recent work involving native gel electrophoresis (Abascal & Zardoya, 2012; Syeda *et al.* 2016).

In addition to inorganic anions, VRAC, or the similar volume-sensitive anion channel, is thought to be permeable to a variety of small organic molecules. These include the negatively charged excitatory amino acids and monocarboxylates (aspartate, glutamate and lactate), weakly charged amino acid zwitterions (such as alanine, glutamine, glycine and taurine), and uncharged polyols (e.g. *myo*-inositol and sorbitol) (Strange *et al.* 1996; Kirk, 1997; Nilius *et al.* 1997; Wehner *et al.* 2003; Pedersen *et al.* 2016). The main evidence for VRAC-mediated transport of organic osmolytes was derived from electrophysiological studies measuring currents carried by organic anions. The electrophysiological findings were corroborated by numerous reports on the shared pharmacological profile of VRAC and a VRAC-like

pathway(s) transporting organic osmolytes (Jackson & Strange, 1993; Boese *et al.* 1996; Strange *et al.* 1996; Kirk, 1997; Nilius *et al.* 1997; Wehner *et al.* 2003; Abdullaev *et al.* 2006). The quantitative contribution of organic osmolyte fluxes to regulatory volume decrease (RVD) varies from strong to negligible, depending on the cell type and cytosolic abundance of organic osmolyte species (Kirk, 1997; Kinne, 1998; Wehner *et al.* 2003). Yet, regardless of the role in cell volume regulation, release of organic molecules has major physiological and pathological significance because many of the released osmolytes possess signalling properties or represent important intracellular metabolites (Kirk, 1997; Mongin, 2016). In the brain, several of the major organic osmolytes, notably glutamate and taurine, act as neurotransmitters and, therefore, the physiological significance of VRAC in this tissue is disproportionately high (Mongin, 2016).

Before the discovery of the LRRC8 family, VRAC involvement in the release of various organic osmolytes was questioned (reviewed in Kirk, 1997; Franco, 2003; Shennan, 2008). Several studies provided substantial albeit indirect evidence that inorganic anions and certain organic molecules, such as taurine, may be transported via separate volume-sensitive pathways (see, for example, Lambert & Hoffmann, 1994; Shennan *et al.* 1994; Mongin *et al.* 1999; Stutzin *et al.* 1999). This idea has been challenged following the identification of LRRC8A. Recent reports provided direct molecular biological evidence for the involvement of LRRC8A in the release of taurine, excitatory amino acids, GABA, glycine, lactate and *myo*-inositol (Hydzinski-Garcia *et al.* 2014; Qiu *et al.* 2014; Voss *et al.* 2014; Gaitan-Penas *et al.* 2016; Lutter *et al.* 2017). Nevertheless, the long-standing question remains: do LRRC8 proteins form a single, 'universal' organic osmolyte channel, or are there multiple swelling-activated release pathways? The first molecular evidence for the diversity of VRAC channels has been provided by T. J. Jentsch's laboratory, which discovered that LRRC8A–LRRC8D heteromers are specifically responsible for swelling-activated release of taurine and uptake of the chemotherapy drug cisplatin (Planells-Cases *et al.* 2015). The same group further explored the definitive contribution of other LRRC8 subunits to release of diverse organic osmolytes (Lutter *et al.*

2017). Our present work adds to existing knowledge in two major ways: using RNAi and double-labelling radiotracer approaches, we shed light on the molecular composition of the native organic osmolyte channels in primary brain cells – astrocytes – and further demonstrate the existence of multiple functionally diverse LRRC8-containing organic osmolyte channels within a single cell type.

Methods

Ethics statement

All animal procedures in this study were approved by the Institutional Animal Care and Use Committee of the Albany Medical College and strictly conformed to the NIH Guidelines for Care and Use of Laboratory Animals.

Primary astrocyte cultures

Primary rat astrocytes were prepared from newborn or 1-day-old Sprague–Dawley rat pups as described in detail elsewhere (Mongin *et al.* 2011). Briefly, postnatal pups of both sexes were killed by rapid decapitation; their cortices were aseptically dissected from the meninges and hippocampi, and collected into ice-cold Opti-MEM. Opti-MEM and all other cell culture components were from Thermo Fisher Scientific (Waltham, MA, USA), unless otherwise specified. The cortical tissue was minced and transferred into a solution of the recombinant protease TrypLE diluted with Opti-MEM (1:1, v/v), and additionally supplemented with DNase I (Sigma-Aldrich, St Louis, MO, USA; 1 mg mL⁻¹). Three enzymatic extractions were carried out at 37°C with continuous slow stirring. The first extraction was discarded and the last two extractions were combined. Brain cells were sedimented by brief centrifugation (1.5 min, ~1000 g), resuspended in minimum essential medium (MEM) containing 10% heat inactivated horse serum (HIHS), and 50 U mL⁻¹ penicillin and 50 µg mL⁻¹ streptomycin (P/S), and then plated on poly-D-lysine-coated T-75 culture flasks at a density of 200,000 cells per flask. The primary cultures were grown in MEM plus 10% HIHS, and antibiotics for 2–3 weeks in a humidified atmosphere of 5% CO₂, balance air at 37°C. Cell culture medium was changed twice per week. Confluent cultures contained 95–98% astrocytes, as periodically checked by staining with monoclonal antibodies against the astroglial cell marker, glial fibrillary acidic protein (Sigma-Aldrich, cat. no. G3893).

siRNA transfection of primary astrocytes

Knockdown of VRAC subunits was performed using siRNA constructs from Qiagen (Valencia, CA, USA), as described elsewhere (Hydzinski-Garcia *et al.* 2014). Briefly, primary astrocytes grown to 80–90% confluency

were transfected using 50 nM siRNA and the Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) as per the manufacturer's instructions. siRNA/Lipofectamine complexes were prepared in Opti-MEM, and then added to cells grown in serum-containing media. After 4-h incubation, the media were completely replaced with fresh MEM+HIHS+P/S. Changes in mRNA expression levels were determined 48 h post transfection and all functional assays were performed at 96 h. As a negative control, we used the AllStars scrambled siRNA from Qiagen. The catalogue numbers and target sequences for all siRNA species are presented in Table 1.

Measurement of mRNA expression levels using qRT-PCR

Relative gene expression and efficacy of RNAi gene knockdowns were determined using quantitative RT-PCR (qRT-PCR). Primary astrocytes grown in 60 mm Petri dishes were transfected as described above. Forty-eight hours post-transfection, mRNA was isolated using the RNAqueous-4PCR kit (Thermo Fisher Scientific) according to the manufacturer's protocol. The isolated mRNA was immediately converted to cDNA using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA). Gene expression levels were analysed by quantitative PCR with the SYBR Green master mix (Bio-Rad) and gene-specific qPCR primers in a CFX96 Real Time PCR set-up (Bio-Rad). The expression levels were normalized within each sample to three housekeeping genes: *RPL13a*, *RPS20* and *GAPDH*. All primers used are listed in Table 1.

Radiotracer amino acid release assays

Release rates for the major intracellular organic osmolytes glutamate, taurine and *myo*-inositol were quantified using the previously established radiotracer efflux assay (Mongin & Kimelberg, 2005b; Bowens *et al.* 2013; Hydzinski-Garcia *et al.* 2014). We used the non-metabolizable glutamate analogue D-[¹⁴C]aspartate (55 mCi mmol⁻¹, American Radiolabelled Chemicals, St Louis, MO, USA), [³H]taurine (20 Ci mmol⁻¹, from either American Radiolabelled Chemicals or Perkin Elmer, Waltham, MA, USA), and *myo*-[³H]inositol (20.1 Ci mmol⁻¹, Perkin Elmer). Primary astrocytes grown to 80–90% confluency on 18 × 18 mm glass coverslips were transfected with siRNA as described above. Prior to transport experiments, cells were loaded overnight with radiolabelled amino acids by incubating them in cell culture medium containing 0.1–0.2 µCi mL⁻¹ D-[¹⁴C]aspartate and 1–2 µCi mL⁻¹ [³H]taurine or 4–6 µCi mL⁻¹ *myo*-[³H]inositol.

Table 1. qPCR primers and siRNA constructs

Target gene	Catalogue no. for qPCR primers	siRNA name (catalogue no.)	siRNA target sequence
NC	N/A	AllStars NC (SI03650318)	Scrambled (proprietary)
<i>LRRC8A</i>	QT01575483	siLRRC8A.4 (SI01725360)	5'-CTCTACCTGAACCGCAACAAA-3'
<i>LRRC8B</i>	QT00434805	siLRRC8B.1 (SI01673007)	5'-ATGGTCTCACGTCGTCCTATA-3'
		siLRRC8B.2 (SI01673014)	5'-CAGATAATCGTCAAAGTCATT-3'
		siLRRC8B.4 (SI01673028)	5'-CTGGCACAATAACATCGCTTA-3'
		siLRRC8C.1 (SI01550815)	5'-TTGGATGTACTTTACAAGTCA-3'
<i>LRRC8C</i>	QT01583897	siLRRC8C.2 (SI01550822)	5'-ACGGCCTGACGTGCCTTTATA-3'
		siLRRC8C.4 (SI01550836)	5'-TCCCGAGAAGTTCGTGGTTGA-3'
		siLRRC8D.1 (SI01904287)	5'-AGGCATTGAATCAAGACGTAA-3'
<i>LRRC8D</i>	QT00370111	siLRRC8D.2 (SI01904294)	5'-CAGCAGTACGTATTATCAAT-3'
		siLRRC8D.4 (SI01904308)	5'-TGCCGTCGCCTGCAAATCAA-3'
		siLRRC8E.2 (SI01665146)	5'-AACGATCAACATATATTTAAG-3'
<i>LRRC8E</i>	QT01591352	siLRRC8E.3 (SI01665153)	5'-ATGCCAAGTCCTTATGTATA-3'
		siLRRC8E.4 (SI01665160)	5'-CAGCTTAGTTAGTTTCTATA-3'
		N/A	N/A
<i>GAPDH</i>	QT00199633	N/A	N/A
<i>RPL13a</i>	QT00178675	N/A	N/A
<i>RPS20</i>	QT00431333	N/A	N/A

All validated qPCR primers and RNAi constructs were from Qiagen. N/A, not applicable; NC, negative control.

To increase experimental throughput, the initial efflux assays were performed in a 12-well plate format. In this experimental design, cells grown in individual wells were washed from extracellular radiotracers, and then pre-incubated in Basal isoosmotic medium that has the following composition (in mM): 135 NaCl, 3.8 KCl, 1.2 MgSO₄, 1.3 CaCl₂, 1.2 KH₂PO₄, 10 D-glucose, 10 Hepes (pH 7.4, osmolarity 290 ± 2 mosmol L⁻¹). The Basal medium was then replaced with Na⁺-free media, in which Na⁺ ions were removed by iso-osmotic replacement of NaCl with LiCl. This was necessary because astrocytes express very high densities of Na⁺-dependent glutamate transporters (GLAST), and in a plate format, re-accumulate a significant fraction of glutamate released during cell swelling (Schober & Mongin, 2015). Experimental media were replaced and collected three times at 10 min intervals. During the last incubation period, cells were challenged with either isoosmotic (as a control) or hypoosmotic (to induce cell swelling) Na⁺-free media. In the hypoosmotic Na⁺-free medium, [LiCl] was reduced by 50 mM while concentrations of all other components remained the same (osmolarity ≈ 200 mosmol L⁻¹, ~30% reduction as compared to isoosmotic conditions). Ten-minute fractions of isoosmotic or hypoosmotic media were manually collected and analysed for the radiotracer content. The integral release values were normalized to the remaining isotope content in cells, which were lysed using a solution of 2% SDS and 8 mM EDTA, and then compared between isoosmotic *versus* hypo-osmotic conditions. ³H and ¹⁴C contents in each vial were determined off-line using a TriCarb 2900 scintillation counter (Perkin Elmer)

after adding Ecoscint A scintillation fluid (National Diagnostics, Atlanta, GA, USA).

The majority of osmolyte efflux assays were performed in a Lucite superfusion chamber that has a depression on the bottom to accommodate an 18 × 18 mm glass coverslip and a Teflon screw lid that leaves a ~200 μm space above the cells. The chamber was continuously perfused with Hepes-buffered Basal medium or hypoosmotic medium at a flow rate of ~1.2 mL min⁻¹, in a thermostat incubator at 37°C. The medium in the chamber was exchanged at least 10 times min⁻¹. Because of the fast superfusion rate, D-[¹⁴C]aspartate reuptake was minimal and all experiments were performed in Na⁺-containing media. The composition of Basal isoosmotic medium is given above. In the hypoosmotic medium, [NaCl] was reduced by 50 mM while concentrations of all other components remained the same (osmolarity ≈ 200 mosmol L⁻¹, ~30% reduction). One-minute superfusate fractions were gathered into scintillation vials using an automated collector. At the end of each experiment, cells were lysed using SDS plus EDTA. The 1-min fractional release rates were calculated in relation to the total ¹⁴C/³H isotope content, which was calculated 'retrospectively' using an Excel-based custom computer program.

Calculations of amino acid net charge

To determine the net charge of the zwitterionic taurine at various pH values, we used a calculation approach based on the Henderson-Hasselbalch ionization equilibrium equation as originally proposed by Moore (1985). The net charge (*Q*) of the negative sulfonic and

positive amino groups were derived from the following equation:

$$Q_{\text{net}} = Q^- + Q^+, \quad \text{where}$$

$$Q^- = (-1)/[1 + 10^{-(\text{pH}-\text{pK}_a)}] \quad \text{and}$$

$$Q^+ = (+1)/[1 + 10^{+(\text{pH}-\text{pK}_a)}]$$

pK_a values of sulfonic and amino groups were accepted as 1.5 and 8.82, respectively. Using these values and calculations, at pH 7.4 only 3.7% of taurine molecules are negatively charged, while at pH 9.8 the fraction of charged molecules reaches ~91%.

Statistical analysis

All data are presented as means \pm SEM. In the majority of cases, statistical differences between experimental groups were determined using one-way ANOVA followed by the Bonferroni *post hoc* test for multiple comparisons. In osmolyte release experiments, we separately evaluated (1) maximal release rates in swollen cells, representing amplitude of VRAC response, and (2) the total integral release under hypoosmotic conditions reflecting 'total' VRAC activity over a 10 min period in cells which actively regulate their volume. We further evaluated the osmolyte release kinetics using a two-way ANOVA with Bonferroni *post hoc* test (only the effects of treatment are presented). Comparisons of normalized expression values were done with Student's one-sample *t* test and a Bonferroni *post hoc* test for multiple comparisons. Prism 5.0 (GraphPad Software, San Diego, CA, USA) was used for statistical analyses. Origin 8.1 (OriginLab, Northhampton, MA, USA) was used for graphing purposes.

Results

Relative expression of LRRC8 subunits and validation of LRRC8 gene-specific siRNA constructs in primary rat astrocytes

To determine the relative expression of all LRRC8 subunits in astrocytes, we performed qRT-PCR analysis. Experiments similar in scope have been conducted in our prior study (Hydzinski-Garcia *et al.* 2014); however, it was important to re-test the relative abundance of the LRRC8 isoforms in primary astrocyte cultures which were utilized in the present work. As shown in Fig. 1A, we found that *LRRC8A*, *B*, *C* and *D* were expressed at very similar levels (100%, 123%, 75% and 130% for *A*, *B*, *C* and *D* subunits, respectively, as normalized to *LRRC8A*). The *LRRC8E* mRNA levels were significantly lower (~5%, as compared to *LRRC8A*).

To knockdown individual LRRC8 subunits, we tested three commercially available siRNAs per subunit,

which targeted distinct regions of each *LRRC8* mRNA species (target sequences shown in Table 1). The *LRRC8A*-targeting siRNAs were validated in our prior work (Hydzinski-Garcia *et al.* 2014), but additionally shown in Fig. 1B for reference purposes. All of the tested siRNAs reduced LRRC8 subunit expression by 60–90%, with some constructs demonstrating more effective knockdown than others (Fig. 1B–F). In all the subsequent functional experiments, we utilized the most effective siRNA species ($\geq 80\%$ efficacy).

Preliminary screens for the role of LRRC8 proteins in swelling-activated release of organic osmolytes

To probe for the relative significance of each of the LRRC8A–E subunits in organic osmolyte release from primary rat astrocytes, we initially used simultaneously measured efflux of [^3H]taurine and D-[^{14}C]aspartate in a multi-well plate format, which allows for a medium-throughput collection of data. As outlined in Methods, these experiments were performed in Na^+ -free hypoosmotic medium to prevent the highly effective reuptake of D-[^{14}C]aspartate by the Na^+ -dependent excitatory amino acid transporter GLAST (Schober & Mongin, 2015). As shown in Fig. 2, the most effective reduction of swelling-activated release of both [^3H]taurine and D-[^{14}C]aspartate was observed with siRNA targeting *LRRC8A* (~70% inhibition). *LRRC8B* knockdown was completely ineffective in blocking release of both radiotracers. Downregulation of *LRRC8C*, *LRRC8D* and *LRRC8E* produced moderate (~25–30%) inhibition of D-[^{14}C]aspartate release (Fig. 2). Efflux of [^3H]taurine was impacted in a similar fashion for *LRRC8C* and *LRRC8E*. However, targeting *LRRC8D* uniquely inhibited the release of [^3H]taurine significantly more as compared to D-[^{14}C]aspartate (Fig. 2, 45% vs. 25%, $P < 0.001$).

RNAi knockdown of LRRC8D potently inhibits swelling-activated release of taurine and myo-inositol with no effect on the efflux of glutamate

Our results on the potential unique role of the LRRC8D protein in VRAC channels contributing to release of [^3H]taurine resemble the recent findings in HEK293 cells (Planells-Cases *et al.* 2015; Lutter *et al.* 2017). To further explore the specific contribution of the LRRC8D subunit in the release of organic osmolytes, we conducted double-label radiotracer assays in a Lucite superfusion set-up, allowing for high temporal resolution collection of data. Rapid medium exchange in the Lucite chamber allowed for the measurement of D-[^{14}C]aspartate release in hypoosmotic medium with 'physiological' Na^+ levels because the speed of perfusion minimizes Na^+ -dependent reuptake of excitatory amino acids. As shown in Fig. 3A, *LRRC8D* knockdown with two independent siRNA

constructs equally and significantly inhibited [^3H]taurine efflux by $\sim 50\%$. In striking contrast, the release of D-[^{14}C]aspartate was essentially insensitive to *LRRC8D* knockdown, even though it was measured in the same cells. As a positive control, knockdown of *LRRC8A* produced a strong and approximately equal inhibition of both [^3H]taurine and D-[^{14}C]aspartate release, again measured in the same cells (compare Fig. 3A and B).

The insensitivity of D-[^{14}C]aspartate release to *LRRC8D* knockdown differed from the data of 'plate' release assays, which demonstrated limited, but statistically significant

inhibition with the same treatment (Fig. 2). Similar trends were observed for knockdowns of *LRRC8C* and *LRRC8E* (see below). These relatively small discrepancies between two assays are likely due to the differences in experimental conditions: 'plate' assays were done in Na^+ -free media, while the Lucite chamber experiments were performed with Na^+ -containing media.

In order to understand the basis for apparent discrimination between [^3H]taurine and D-[^{14}C]aspartate by the *LRRC8D*-containing VRAC, we explored the effect of *LRRC8D* siRNA on the release of the




Figure 1. Relative mRNA expression levels for five members of the LRRC8 protein family and validation of RNAi knockdown of each of the five subunits in primary rat astrocytes

A, quantification of mRNA expression levels for *LRRC8A–E* using qRT-PCR. Expression levels were normalized to ribosomal *RPL13a* within the same samples. Data are the mean values \pm SEM of 6 independently prepared astrocytic cultures. B–F, effects of gene-specific *LRRC8* siRNA constructs on mRNA expression levels measured 48 h post-transfection. *LRRC8A* knockdown data are derived from Hyzinski-García *et al.* (2014) with permission. *LRRC8B–E* knockdown results are the means \pm SEM of 3–4 independent transfections in at least 3 different astrocytic cultures. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ vs. siNC (negative control siRNA). NTF, non-transfected cells.

uncharged polyol *myo*-[³H]inositol. As seen in Fig. 4, two independent siRNA constructs which targeted *LRRC8D* nearly completely inhibited swelling-activated

myo-[³H]inositol efflux. The same degree of inhibition was seen in cells treated with the *LRRC8A* siRNA (Fig. 4). These data strongly suggest that LRRC8A/LRRC8D heteromers represent the main permeability route for *myo*-[³H]inositol.




Figure 2. Preliminary screening for the effects of *LRRC8A–E* siRNAs on swelling-activated D-[¹⁴C]aspartate and [³H]taurine release from primary astrocytes

Astrocytes grown on 12-well plates were transfected with gene-specific *LRRC8* siRNAs. Ninety-six hours post-transfection, [³H]taurine and D-[¹⁴C]aspartate release values were measured *simultaneously* in cells preloaded with both radiotracers. Integral 10-min release values were quantified for isoosmotic (290 mosmol L⁻¹) or hypoosmotic (200 mosmol L⁻¹) conditions. Na⁺-free media was used to prevent D-[¹⁴C]aspartate reuptake (see Methods). Data are the means ± SEM of 6–9 independent experiments per treatment group and 18 controls, performed in at least 2 different astrocyte cultures. ***P* < 0.01, ****P* < 0.001, vs. negative control siRNA (siNC). ###*P* < 0.001 [³H]taurine vs. D-[¹⁴C]aspartate release.

Combined siRNA knockdown of *LRRC8C* and *LRRC8E* suppresses efflux of glutamate with no impact on release of taurine or *myo*-inositol

Based on the data presented here and elsewhere (Planells-Cases *et al.* 2015; Lutter *et al.* 2017), LRRC8A/D heteromers are likely responsible for the release of uncharged osmolytes, such as taurine and *myo*-inositol. The molecular composition of the release pathway for charged osmolytes including the excitatory amino acids glutamate and aspartate is less clear. To address this gap in knowledge, we measured osmolyte release kinetics in astrocytes treated with siRNAs targeting *LRRC8C* and *LRRC8E*. Individual knockdowns of *LRRC8C* and *LRRC8E* produced no significant impact on the efflux of [³H]taurine (Fig. 5A) or D-[¹⁴C]aspartate (Fig. 5B). We next performed double knockdown of *LRRC8C* and *LRRC8E*, which again produced no effect on the release of [³H]taurine (Fig. 6A), but *in the same cells* significantly reduced efflux of D-[¹⁴C]aspartate by ~40% (Fig. 6B, *P* < 0.01). The additive effects of *LRRC8C* and *LRRC8E* deletion suggest that these subunits are mutually replaceable and together are responsible for the movement of negatively charged amino acids.

To further verify the unique contribution of *LRRC8C* and *LRRC8E* subunits to movement of charged molecules, we measured the effect of *LRRC8C* and *LRRC8E* siRNAs




Figure 3. Effects of the *LRRC8A* or *LRRC8D* RNAi knockdowns on swelling-activated efflux of [³H]taurine (A) and D-[¹⁴C]aspartate (B)

Astrocytic [³H]taurine and D-[¹⁴C]aspartate release kinetics were measured *simultaneously* in cells preloaded with both radiotracers. Cells were transfected with negative control siRNA (siNC) or gene specific siLRRC8A, siLRRC8D_1, or siLRRC8D_2. For clarity, the results with [³H]taurine and D-[¹⁴C]aspartate are presented in separate panels. Data are the means ± SEM of 6–7 independent experiments per group performed in 3 different astrocyte cultures. ****P* < 0.001 maximal release values vs. siNC; ###*P* < 0.001 integral 10-min release values vs. siNC.

on the efflux of the uncharged *myo*-[³H]inositol. Similar to the results seen with [³H]taurine (Fig. 6A), knockdown of *LRRC8C* or *E*, individually or in combination, had no effect on the efflux of *myo*-[³H]inositol (Fig. 7).

LRRC8C/D knockdown potentially inhibits the release of both [³H]taurine and D-[¹⁴C]aspartate

To complete our systematic evaluation of the contribution of LRRC8 subunits to the release of organic osmolytes,




Figure 4. Effects of *LRRC8A* or *LRRC8D* knockdowns on the swelling-activated release of *myo*-[³H]inositol

Hypotonic medium-activated *myo*-[³H]inositol efflux was measured in cells transfected with negative control siRNA (siNC) or the gene-specific siLRRC8A, siLRRC8D_1, or siLRRC8D_2. Data are the means \pm SEM of 6–8 independent experiments per group performed in 2 astrocyte cultures. ** $P < 0.01$, *** $P < 0.001$, maximal release values vs. negative control siRNA (siNC); # $P < 0.05$, ## $P < 0.01$ integral 10-min release values vs. siNC.

we additionally performed combined knockdowns of *LRRC8C* and *LRRC8D*. Perhaps most surprisingly, we found that simultaneous downregulation of *LRRC8C* and *LRRC8D* dramatically inhibited the efflux of both [³H]taurine and D-[¹⁴C]aspartate measured in the same cells (Fig. 6A and B). The degree of inhibition for the two radiotracers was very similar to the effects of deletion of the essential VRAC subunit LRRC8A (compare Fig. 6 to Fig. 3). Overall, these findings are inconsistent with a simple model suggesting that LRRC8D is present only in the ‘uncharged osmolyte’ channel (for further discussion, see the following sections).

Modification of amino acid charge with pH changes eliminates sensitivity of [³H]taurine release to *LRRC8D* knockdown

To further explore the idea that charged and uncharged organic osmolytes are released via separate swelling-activated pathways, we used varying pH conditions to alter the charge on the zwitterionic taurine. This manoeuvre has been extensively used in the past for measuring taurine currents via VRAC (Jackson & Strange, 1993; Boese *et al.* 1996). At physiological pH 7.4, <4% of taurine is negatively charged, while the bulk of taurine molecules are electroneutral. Changing the pH to 9.8 makes ~91% of taurine molecules negatively charged (see Methods). At pH 7.4, knockdown of *LRRC8D* causes a significant reduction in the [³H]taurine efflux rates (Figs 2 and 3, and new data in Fig. 8) by as much as ~50%. When compared side-by-side in the multi-well plate format, changing pH from 7.4 to pH 9.8 completely eliminated the sensitivity of taurine release to *LRRC8D* knockdown (Fig. 8A). To prove that this effect is specific,




Figure 5. Effects of *LRRC8C* or *LRRC8E* knockdown on astrocytic swelling-activated efflux of [³H]taurine (A) and D-[¹⁴C]aspartate (B)

Cells were transfected with negative control siRNA (siNC), or the gene-specific siLRRC8C or siLRRC8E. [³H]Taurine and D-[¹⁴C]aspartate release rates were measured *simultaneously* in cells preloaded with both radiotracers. Data are the means \pm SEM of 4–5 independent experiments per group performed in 3 different astrocyte cultures.

we additionally downregulated the LRRC8A subunit, and found that [^3H]taurine efflux is blunted independently of pH of the assay media (Fig. 8A). Since alkaline conditions strongly increased [^3H]taurine release, we normalized the data to the negative control siRNA-treated cells at the same pH for a clearer comparison (Fig. 8B). Overall, the results of these experiments suggest that switching the charge of the taurine molecule from neutral to charged, diverts its movement from the LRRC8A/D containing VRAC heteromers to another permeability pathway that incorporates LRRC8A but does not depend on LRRC8D (see additional discussion below).

Discussion

In the present study, we extensively characterized the contribution of the recently discovered LRRC8 proteins to swelling-activated organic osmolyte release in cultured primary astrocytes, the cell type that is central to cell volume control in the CNS (see discussion in Mongin, 2016). In addition to the previously established critical role of LRRC8A, we identified (1) preferential dependence of the efflux of uncharged organic osmolytes on the expression levels of *LRRC8D*, and (2) selective sensitivity of the movement of the charged organic osmolytes on the presence of LRRC8C and LRRC8E. Although further biophysical studies are needed to establish the exact stoichiometry of the LRRC8-containing glial VRACs, the simplest deduction from our work is that LRRC8A/D heteromers form a conduit for the release of uncharged organic molecules, while a more complex assembly containing LRRC8A, C, D and E creates a separate pathway

that preferentially moves negatively charged osmolytes. The hypothetical composition of the two glial VRACs is shown in Fig. 9 and discussed below. These and other findings of the current work demonstrate the co-existence of at least two functionally distinct LRRC8-containing heteromeric VRAC channels in rat astrocytes.

The existence of the LRRC8A/D-containing channel for neutral organic osmolytes is firmly supported by our present findings and recently published data. Planells-Cases *et al.* (2015) were the first to report that deletion of *LRRC8D* eliminates swelling-activated release of [^3H]taurine and uptake of the electroneutral chemotherapeutic agent cisplatin in KBM7 and HEK293 cells. Subsequently, a study from the same group recapitulated near complete dependence of [^3H]taurine efflux on expression of *LRRC8D*, and found similar trends for swelling-activated fluxes of *myo*-[^3H]inositol and [^3H]GABA in HEK293 cells (Lutter *et al.* 2017). Importantly, the release of all three osmolytes were rescued by heteroexpressing the combination of LRRC8A and LRRC8D subunits in erase-and-replace experiments. Therefore, the LRRC8A/D heteromers are sufficient to mediate volume-dependent release of certain organic molecules. In our hands, *LRRC8D* knockdown reduced release of [^3H]taurine by $\sim 50\%$ only, but completely inhibited efflux of *myo*-[^3H]inositol. Importantly, in the same cells, we observed no significant impact on *simultaneously* measured transport of the negatively charged D-[^{14}C]aspartate. The acidic amino acids aspartate and glutamate have isoelectric point (pI) values of 2.77 and 3.2, respectively, and are negatively charged at pH 7.4. The polyol *myo*-inositol has no group capable




Figure 6. Effects of the double knockdowns of *LRRC8C+E* or *LRRC8C+D* on the swelling-activated efflux of [^3H]taurine (A) and D-[^{14}C]aspartate (B)

Astrocytes were transfected with negative control siRNA (siNC) or the gene-specific siLRRC8C plus siLRRC8E, or siLRRC8C plus siLRRC8D. [^3H]Taurine and D-[^{14}C]aspartate release rates were measured *simultaneously* in cells preloaded with both radiotracers. Data are the means \pm SEM of 4–5 independent experiments per group performed in 3 different astrocyte cultures. ** $P < 0.01$, *** $P < 0.001$, maximal release values vs. siNC; ### $P < 0.001$, integral 10-min release values vs. siNC.

of ionization and is therefore completely uncharged. The zwitterionic taurine has a pI value of 5.16, translating to <4% of the molecules carrying negative charge at pH 7.4. When we modified pH to 9.8, which makes ~91% of taurine molecules negatively charged, [³H]taurine efflux was no longer affected by the deletion of LRRC8D. However, the inhibitory effects of *LRRC8A* knockdown were equally strong at pH 7.4 and 9.8. These data clearly point to the presence of an alternative native channel for

negatively charged molecules, which requires LRRC8A but is not critically dependent on LRRC8D.

The molecular composition of glial VRAC, which accommodates charged organic osmolytes, appears to be complex. By the process of elimination and mRNA expression data, we first tested if LRRC8A/C heteromers mediate the movement of charged molecules. In high resolution efflux assays, deletion of LRRC8C produced no significant impact on the D-[¹⁴C]aspartate release rates. Similarly, deletion of LRRC8E was also ineffective. Only when *LRRC8C* and *LRRC8E* siRNAs were combined, D-[¹⁴C]aspartate (but not [³H]taurine) fluxes were strongly inhibited. On the surface, it means that both LRRC8C and LRRC8E determine the selectivity of the LRRC8-containing VRAC for charged molecules, and that these subunits are mutually replaceable. This idea is consistent, at least in part, with the literature findings that LRRC8A/E, and to a lesser degree, LRRC8A/C heteromers are capable of sustaining D-[¹⁴C]aspartate efflux in HEK293 cells (Lutter *et al.* 2017). Lutter *et al.* suggested that LRRC8E is the primary component of the swelling-activated release pathway for charged molecules. This appears not to be the case in rat astrocytes, perhaps due to the low levels of LRRC8E expression. The most perplexing finding of our present work was the dramatic inhibition of D-[¹⁴C]aspartate efflux by combination of *LRRC8C*+*LRRC8D* siRNAs. This synergistic action is inconsistent with the idea that LRRC8D is present only in the 'electroneutral' channel, but could be explained by the fact that deletion of LRRC8C and LRRC8D would leave only LRRC8A and E and there is not sufficient




Figure 7. Effects of *LRRC8C*, *LRRC8E* or *LRRC8C+E* knockdowns on the swelling-activated release of myo-[³H]inositol

Astrocytes were transfected with the negative control siRNA (siNC) or the gene-specific siLRRC8C, siLRRC8E, or siLRRC8C+siLRRC8E. Data are the means \pm SEM of 6–8 independent experiments per group performed in 2 astrocyte cultures.




Figure 8. Effect of extracellular pH on the sensitivity of [³H]taurine release to the knockdown of *LRRC8A* or *LRRC8D*

A, 10-min [³H]taurine release values were determined in cells treated with negative control siRNA (siNC), siLRRC8A or siLRRC8D. Cells were exposed to either isoosmotic (290 mosmol L⁻¹) or hypoosmotic (200 mosmol L⁻¹) Na⁺-free media in which pH values were adjusted to 7.4 (black bars), or 9.8 (grey bars). Data are the means \pm SEM of 6–9 independent experiments per group performed in 2 different astrocyte cultures. ****P* < 0.001, vs. siNC isoosmotic release values under the same pH conditions. ###*P* < 0.001, vs. hypoosmotic release values in siNC-treated cells under the same pH conditions. **B**, the same data as in the left panel were normalized to siNC hypoosmotic release values under matching pH conditions. ****P* < 0.001, vs. hypoosmotic release in siNC group; ###*P* < 0.001, effects of siRNA at pH 7.4 vs. pH 9.8.

LRRC8E to sustain functional channels. Therefore, the simplest explanation for our finding is presented in Fig. 9. We think that in astroglial cells, LRRC8A partners with LRRC8C, LRRC8E and LRRC8D to form a permeability pathway for charged molecules. An alternative explanation for our siRNA results targeting charged osmolyte release would be that D- ^{14}C aspartate fluxes are shared between two heteromeric channels composed of LRRC8A/C/E and LRRC8A/D subunits. In this case, combined deletion of LRRC8C and LRRC8D subunits would also strongly impact both release pathways. Yet, this latter hypothesis is poorly compatible with our experimental results, namely negligible sensitivity of the swelling-activated D- ^{14}C aspartate transport to single deletion of either LRRC8C or LRRC8D.

A separate brief discussion ought to be dedicated to the role of LRRC8B, which is abundantly expressed in rat astrocytes (our data) and the forebrain tissue (Roth *et al.* 2006). Prior studies consistently found that LRRC8A/B heteromers are insufficient to sustain VRAC Cl^- currents or organic osmolyte release (Voss *et al.* 2014; Gaitan-Penas *et al.* 2016; Lutter *et al.* 2017). Yet, incorporation of LRRC8B into complexes of other LRRC8 heteromers may modify the biophysical properties (Lutter *et al.* 2017). In our multi-well plate assays, we found no evidence of functional effects of LRRC8B deletion when it was targeted alone (Fig. 2) or in combination with LRRC8C or LRRC8D (data not shown). Therefore, at this stage, LRRC8B appears to be a 'silent' partner in formation of astrocytic VRACs, and its presence in organic osmolyte release pathways is uncertain. These negative findings should not discourage future additional LRRC8B work, as this protein has been identified as one of the consistently

downregulated transcripts in brain tissue surrounding haemorrhage and lacunar strokes (Rosell *et al.* 2011).

The existence of separate swelling-activated release pathways for glutamate/aspartate and taurine has important implications for brain physiology. In the central nervous system, glutamate is the most abundant organic osmolyte, which happens to serve as the main excitatory neurotransmitter (Meldrum, 2000). The aminosulfonic acid taurine is also one of the most abundant osmolytes in brain tissue, and acts as an endogenous agonist of the inhibitory glycine and GABA_A receptors (Albrecht & Schousboe, 2005). Traditionally, neurons are considered the main source of neurotransmitter release, but recent work in the field pointed to astrocytes as a source of numerous biologically active molecules ('gliotransmitters'), including glutamate and taurine (Haydon & Carmignoto, 2006). VRAC is just one among numerous gliotransmitter release routes (Malarkey & Parpura, 2008; Hamilton & Attwell, 2010), but it may be disproportionately important in astrocytes. For example, in the hypothalamus and pituitary, specialized subpopulations of astrocytes contain high levels of taurine and release it in an osmosensitive fashion. Such taurine release modulates the activity of vasopressin-releasing neurons and, consequently, whole-body fluid homeostasis (reviewed in Hussy *et al.* 2000). In the context of neuropathologies, VRAC may be strongly activated due to profound astrocytic swelling in stroke, traumatic brain injury, hyponatremia and epilepsy (reviewed in Mongin & Kimelberg, 2005a; Mongin, 2016). As a consequence of VRAC opening, astrocytes are thought to release vast quantities of glutamate and contribute to tissue damage via excessive activation of glutamate receptors. The present work provides an intriguing possibility of discrete modulation of excitatory (glutamate and aspartate) and inhibitory (taurine and glycine) gliotransmitter release pathways by targeting different subunits of the heteromeric LRRC8 channels.




Figure 9. Graphical summary of RNAi analysis of VRAC composition in rat astrocytes

Cell swelling activates at least two populations of heteromeric VRAC channels. LRRC8A/LRRC8D-containing heteromers dominate the release of the uncharged osmolytes myo-inositol (Ino) and taurine (Tau) with limited movement of charged molecules (thin dotted line). A separate subset of LRRC8A/C/D/E-containing heteromers are permeable to anionic glutamate (Glu^-) and aspartate, and also conduct taurine in its anionic form (Tau^-). [Colour figure can be viewed at wileyonlinelibrary.com]

References

- Abascal F & Zardoya R (2012). LRRC8 proteins share a common ancestor with pannexins, and may form hexameric channels involved in cell-cell communication. *Bioessays* **34**, 551–560.
- Abdullaev IF, Rudkouskaya A, Schools GP, Kimelberg HK & Mongin AA (2006). Pharmacological comparison of swelling-activated excitatory amino acid release and Cl^- currents in rat cultured astrocytes. *J Physiol* **572**, 677–689.
- Albrecht J & Schousboe A (2005). Taurine interaction with neurotransmitter receptors in the CNS: an update. *Neurochem Res* **30**, 1615–1621.
- Boese SH, Wehner F & Kinne RK (1996). Taurine permeation through swelling-activated anion conductance in rat IMCD cells in primary culture. *Am J Physiol Renal Physiol* **271**, F498–F507.

- Bowens NH, Dohare P, Kuo YH & Mongin AA (2013). DCPIB, the proposed selective blocker of volume-regulated anion channels, inhibits several glutamate transport pathways in glial cells. *Mol Pharmacol* **83**, 22–32.
- Cahalan MD & Lewis RS (1988). Role of potassium and chloride channels in volume regulation by T lymphocytes. *Soc Gen Physiol Ser* **43**, 281–301.
- Franco R (2003). Osmosensitive taurine release: does taurine share the same efflux pathway with chloride and other amino acid osmolytes? *Adv Exp Med Biol* **526**, 189–196.
- Gaitan-Penas H, Gradogna A, Laparra-Cuervo L, Solsona C, Fernandez-Duenas V, Barrallo-Gimeno A, Ciruela F, Lakadamyali M, Pusch M & Estevez R (2016). Investigation of LRRC8-mediated volume-regulated anion currents in *Xenopus* oocytes. *Biophys J* **111**, 1429–1443.
- Hamilton NB & Attwell D (2010). Do astrocytes really exocytose neurotransmitters? *Nat Rev Neurosci* **11**, 227–238.
- Haydon PG & Carmignoto G (2006). Astrocyte control of synaptic transmission and neurovascular coupling. *Physiol Rev* **86**, 1009–1031.
- Hazama A & Okada Y (1988). Ca²⁺ sensitivity of volume-regulatory K⁺ and Cl⁻ channels in cultured human epithelial cells. *J Physiol* **402**, 687–702.
- Hoffmann EK, Lambert IH & Pedersen SF (2009). Physiology of cell volume regulation in vertebrates. *Physiol Rev* **89**, 193–277.
- Hussy N, Deleuze C, Desarmenien MG & Moos FC (2000). Osmotic regulation of neuronal activity: a new role for taurine and glial cells in a hypothalamic neuroendocrine structure. *Prog Neurobiol* **62**, 113–134.
- Hydzinski-Garcia MC, Rudkouskaya A & Mongin AA (2014). LRRC8A protein is indispensable for swelling-activated and ATP-induced release of excitatory amino acids in rat astrocytes. *J Physiol* **592**, 4855–4862.
- Jackson PS & Strange K (1993). Volume-sensitive anion channels mediate swelling-activated inositol and taurine efflux. *Am J Physiol Cell Physiol* **265**, C1489–C1500.
- Jentsch TJ (2016). VRACs and other ion channels and transporters in the regulation of cell volume and beyond. *Nat Rev Mol Cell Biol* **17**, 293–307.
- Kinne RK (1998). Mechanisms of osmolyte release. *Contrib Nephrol* **123**, 34–49.
- Kirk K (1997). Swelling-activated organic osmolyte channels. *J Membr Biol* **158**, 1–16.
- Lambert IH & Hoffmann EK (1994). Cell swelling activates separate taurine and chloride channels in Ehrlich mouse ascites tumor cells. *J Membr Biol* **142**, 289–298.
- Lang F, Busch GL, Ritter M, Volkl H, Waldegger S, Gulbins E & Haussinger D (1998). Functional significance of cell volume regulatory mechanisms. *Physiol Rev* **78**, 247–306.
- Lutter D, Ullrich F, Lueck JC, Kempa S & Jentsch TJ (2017). Selective transport of neurotransmitters and modulators by distinct volume-regulated LRRC8 anion channels. *J Cell Sci* **130**, 1122–1133.
- Malarkey EB & Parpura V (2008). Mechanisms of glutamate release from astrocytes. *Neurochem Int* **52**, 142–154.
- Meldrum BS (2000). Glutamate as a neurotransmitter in the brain: review of physiology and pathology 2. *J Nutr* **130**, 1007S–1015S.
- Mongin AA (2016). Volume-regulated anion channel—a frenemy within the brain. *Pflugers Arch* **468**, 421–441.
- Mongin AA, Hydzinski-Garcia MC, Vincent MY & Keller RW Jr (2011). A simple method for measuring intracellular activities of glutamine synthetase and glutaminase in glial cells. *Am J Physiol Cell Physiol* **301**, C814–C822.
- Mongin AA & Kimelberg HK (2005a). Astrocytic swelling in neuropathology. In *Neuroglia*, ed. Kettenmann H & Ransom BR, pp. 550–562. Oxford University Press, Oxford/New York.
- Mongin AA & Kimelberg HK (2005b). ATP regulates anion channel-mediated organic osmolyte release from cultured rat astrocytes via multiple Ca²⁺-sensitive mechanisms. *Am J Physiol Cell Physiol* **288**, C204–C213.
- Mongin AA & Orlov SN (2001). Mechanisms of cell volume regulation and possible nature of the cell volume sensor. *Pathophysiology* **8**, 77–88.
- Mongin AA, Reddi JM, Charniga C & Kimelberg HK (1999). [³H]Taurine and D-[³H]aspartate release from astrocyte cultures are differently regulated by tyrosine kinases. *Am J Physiol Cell Physiol* **276**, C1226–C1230.
- Moore DS (1985). Amino acid and peptide net charges: a simple calculation procedure. *Biochem Educ* **13**, 10–11.
- Nilius B, Eggermont J, Voets T, Buyse G, Manolopoulos V & Droogmans G (1997). Properties of volume-regulated anion channels in mammalian cells. *Prog Biophys Mol Biol* **68**, 69–119.
- Okada Y (1997). Volume expansion-sensing outward-rectifier Cl⁻ channel: fresh start to the molecular identity and volume sensor. *Am J Physiol Cell Physiol* **273**, C755–C789.
- Pedersen SF, Okada Y & Nilius B (2016). Biophysics and physiology of the volume-regulated anion channel (VRAC)/volume-sensitive outwardly rectifying anion channel (VSOR). *Pflugers Arch* **468**, 371–383.
- Planells-Cases R, Lutter D, Guyader C, Gerhards NM, Ullrich F, Elger DA, Kucukosmanoglu A, Xu G, Voss FK, Reincke SM, Stauber T, Blomen VA, Vis DJ, Wessels LF, Brummelkamp TR, Borst P, Rottenberg S & Jentsch TJ (2015). Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs. *EMBO J* **34**, 2993–3008.
- Qiu Z, Dubin AE, Mathur J, Tu B, Reddy K, Miraglia LJ, Reinhardt J, Orth AP & Patapoutian A (2014). SWELL1, a plasma membrane protein, is an essential component of volume-regulated anion channel. *Cell* **157**, 447–458.
- Rosell A, Vilalta A, Garcia-Berrocso T, Fernandez-Cadenas I, Domingues-Montanari S, Cuadrado E, Delgado P, Ribo M, Martinez-Saez E, Ortega-Aznar A & Montaner J (2011). Brain perihematoma genomic profile following spontaneous human intracerebral hemorrhage. *PLoS One* **6**, e16750.
- Roth RB, Hevezi P, Lee J, Willhite D, Lechner SM, Foster AC & Zlotnik A (2006). Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. *Neurogenetics* **7**, 67–80.
- Schober AL & Mongin AA (2015). Intracellular levels of glutamate in swollen astrocytes are preserved via neurotransmitter reuptake and de novo synthesis: implications for hyponatremia. *J Neurochem* **135**, 176–185.

- Shennan DB (2008). Swelling-induced taurine transport: relationship with chloride channels, anion-exchangers and other swelling-activated transport pathways. *Cell Physiol Biochem* **21**, 15–28.
- Shennan DB, McNeillie SA & Curran DE (1994). The effect of a hyposmotic shock on amino acid efflux from lactating rat mammary tissue: stimulation of taurine and glycine efflux via a pathway distinct from anion exchange and volume-activated anion channels. *Exp Physiol* **79**, 797–808.
- Stauber T (2015). The volume-regulated anion channel is formed by LRRC8 heteromers – molecular identification and roles in membrane transport and physiology. *Biol Chem* **396**, 975–990.
- Strange K, Emma F & Jackson PS (1996). Cellular and molecular physiology of volume-sensitive anion channels. *Am J Physiol Cell Physiol* **270**, C711–C730.
- Stutzin A, Torres R, Oporto M, Pacheco P, Eguiguren AL, Cid LP & Sepulveda FV (1999). Separate taurine and chloride efflux pathways activated during regulatory volume decrease. *Am J Physiol Cell Physiol* **277**, C392–C402.
- Syeda R, Qiu Z, Dubin AE, Murthy SE, Florendo MN, Mason DE, Mathur J, Cahalan SM, Peters EC, Montal M & Patapoutian A (2016). LRRC8 proteins form volume-regulated anion channels that sense ionic strength. *Cell* **164**, 499–511.
- Voss FK, Ullrich F, Munch J, Lazarow K, Lutter D, Mah N, Andrade-Navarro MA, von Kries JP, Stauber T & Jentsch TJ (2014). Identification of LRRC8 heteromers as an essential component of the volume-regulated anion channel VRAC. *Science* **344**, 634–638.
- Wehner F, Olsen H, Tinel H, Kinne-Saffran E & Kinne RKH (2003). Cell volume regulation: osmolytes, osmolyte transport, and signal transduction. *Rev Physiol Biochem Pharmacol* **148**, 1–80.

Additional information

Competing interests

The authors declare that they have no competing interests.

Author contributions

A.L.S., C.S.W. and A.A.M. designed the project. A.L.S. and C.S.W. performed experiments. A.L.S., C.S.W. and A.A.M. analysed and interpreted the data. A.L.S., C.S.W. and A.A.M. wrote the paper. All authors approved the final version of the manuscript and agreed to be accountable for all aspects of the work. All persons designated as authors qualify for authorship, and all those who qualify for authorship are listed.

Funding

This study was supported by a grant from the National Institutes of Health (R01 NS061953) to A.A.M.